{"id":47569,"date":"2022-08-23T13:02:02","date_gmt":"2022-08-23T11:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/"},"modified":"2022-08-23T13:02:02","modified_gmt":"2022-08-23T11:02:02","slug":"mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/","title":{"rendered":"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer"},"content":{"rendered":"
\n

WALTHAM, Mass.–(BUSINESS WIRE)–Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer. The company also announced that Mythic co-founder and CEO Alex Nichols, PhD, has transitioned in order to pursue new opportunities.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cWe are delighted to have Dr. Gallant join our team at Mythic,\u201d said Brian Fiske, PhD, Co-founder and Chief Scientific Officer. \u201cHis extensive experience in oncology drug development, in particular antibody-drug conjugates, and proven track record building and leading global clinical development teams will strengthen our capability to pursue the clinical development of our lead program in lung cancer as well as our broader product pipeline.\u201d\n<\/p>\n

\nAs Chief Development Officer, Dr. Gallant is responsible for the strategy, direction, and execution of the company\u2019s clinical development program. He will provide leadership and direction to Clinical Operations, Clinical Sciences, Data Management\/Biometrics, and Drug Safety.\n<\/p>\n

\nDr. Gallant joins Mythic from Daiichi Sankyo, where he was Senior Vice President Global Head of Oncology Clinical Development and led the development of the company\u2019s global oncology portfolio. At Daiichi, he built and led the team that guided the clinical development, the global regulatory submission and worldwide approval of the antibody-drug conjugate Enhertu\u00ae for the treatment of patients with advanced breast cancer, gastric cancer and lung cancer (NSCLC).\n<\/p>\n

\nDr. Gallant previously held leadership roles in clinical oncology at Bristol Myers Squibb, Human Genome Sciences and Biomarin, leading programs for Taxol\u00ae<\/span> and Talzenna\u2122<\/span>. He received his doctorate in medicinal chemistry and bachelor\u2019s degree in pharmacy from the Universit\u00e9 de Montr\u00e9al in Qu\u00e9bec, Canada and is a Fellow of the Order of Pharmacists of Qu\u00e9bec (FOPQ).\n<\/p>\n

\n\u201cI am delighted to be joining Mythic\u2019s leadership team at an exciting time for the company and the field of ADCs,\u201d said Dr. Gallant. \u201cIt is an extraordinary opportunity to blend the experience I have gained in research and development of ADCs in oncology with a truly creative approach to dramatically improve their clinical performance in both efficacy and safety.”\n<\/p>\n

\n\u201cOn behalf of the entire Board of Directors, I want to welcome Gilles to Mythic as well as extend our sincere appreciation to Alex for his dedication and contributions to Mythic since its founding in 2017,\u201d said Bryan Roberts, Partner of Venrock and a member of Mythic\u2019s Board of Directors. \u201cBeginning with nothing other than a mission to improve patient care, over the last five years Mythic has built a strong foundation and world-class team. The company is well-positioned to develop a pipeline of safer and more effective ADCs, beginning with its lead program.\u201d\n<\/p>\n

\nThe Mythic Board of Directors has initiated a search for Dr. Nichols\u2019 successor. In the interim, Brian Fiske, PhD, Co-founder, and Chief Scientific Officer and Sandra Poole, MASc, PEng, Chief Operating Officer, together with Dr. Gallant, have assumed responsibilities for the operational management of the Company.\n<\/p>\n

\nAbout Mythic Therapeutics<\/b>\n<\/p>\n

\nMythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company\u2019s FateControl technology specifically enhances ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the disease and patient profiles that can be treated with Mythic\u2019s ADCs. The Company\u2019s major investors include Venrock, Viking Global Investors, and First Round Capital.\n<\/p>\n

\nFor more information, visit: www.mythictx.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMariesa Kemble
\n
kemblem@mac.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass.–(BUSINESS WIRE)–Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer. The company also announced that Mythic co-founder and CEO Alex Nichols, PhD, has … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-47569","6":"format-standard","7":"category-industry"},"yoast_head":"\nMythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass.–(BUSINESS WIRE)–Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer. The company also announced that Mythic co-founder and CEO Alex Nichols, PhD, has ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-23T11:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220822005749\/en\/1550841\/21\/Gilles_Gallant_-_2021-08_-_02.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer\",\"datePublished\":\"2022-08-23T11:02:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/\"},\"wordCount\":602,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220822005749\\\/en\\\/1550841\\\/21\\\/Gilles_Gallant_-_2021-08_-_02.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/\",\"name\":\"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220822005749\\\/en\\\/1550841\\\/21\\\/Gilles_Gallant_-_2021-08_-_02.jpg\",\"datePublished\":\"2022-08-23T11:02:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220822005749\\\/en\\\/1550841\\\/21\\\/Gilles_Gallant_-_2021-08_-_02.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220822005749\\\/en\\\/1550841\\\/21\\\/Gilles_Gallant_-_2021-08_-_02.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/","og_locale":"en_US","og_type":"article","og_title":"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer - Pharma Trend","og_description":"WALTHAM, Mass.–(BUSINESS WIRE)–Mythic Therapeutics, a biotechnology company focused on the development of antibody-drug conjugate-based therapies for the treatment of a wide range of cancers, announced today the appointment of Gilles Gallant, BPharm, PhD, FOPQ, to the new position of Chief Development Officer. The company also announced that Mythic co-founder and CEO Alex Nichols, PhD, has ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-23T11:02:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220822005749\/en\/1550841\/21\/Gilles_Gallant_-_2021-08_-_02.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer","datePublished":"2022-08-23T11:02:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/"},"wordCount":602,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220822005749\/en\/1550841\/21\/Gilles_Gallant_-_2021-08_-_02.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/","url":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/","name":"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220822005749\/en\/1550841\/21\/Gilles_Gallant_-_2021-08_-_02.jpg","datePublished":"2022-08-23T11:02:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220822005749\/en\/1550841\/21\/Gilles_Gallant_-_2021-08_-_02.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220822005749\/en\/1550841\/21\/Gilles_Gallant_-_2021-08_-_02.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/mythic-therapeutics-announces-appointment-of-gilles-gallant-bpharm-phd-fopq-as-chief-development-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47569"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47569\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}